S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Price:
7.01
HKD
-3.44%
Market Closed
Market Cap:
HK$4.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Shandong Boan Biotechnology Co Ltd
HKEX:6955
|
CN |
|
Nila Infrastructures Ltd
NSE:NILAINFRA
|
IN |
|
Waskita Karya (Persero) Tbk PT
IDX:WSKT
|
ID |
|
M
|
Mondelez International Inc
LSE:0R0G
|
US |
|
J
|
Jiangxi Synergy Pharmaceutical Co Ltd
SZSE:300636
|
CN |
|
A
|
Arise AB
STO:ARISE
|
SE |
Balance Sheet
Balance Sheet Decomposition
Shandong Boan Biotechnology Co Ltd
Shandong Boan Biotechnology Co Ltd
Balance Sheet Decomposition is not available for
Shandong Boan Biotechnology Co Ltd
Shandong Boan Biotechnology Co Ltd
Balance Sheet
Shandong Boan Biotechnology Co Ltd
Shandong Boan Biotechnology Co Ltd
Currency: CNY
| Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & Cash Equivalents |
4
|
532
|
233
|
202
|
199
|
|
| Cash Equivalents |
4
|
532
|
233
|
202
|
199
|
|
| Short-Term Investments |
0
|
82
|
0
|
0
|
0
|
|
| Total Receivables |
31
|
126
|
227
|
293
|
515
|
|
| Accounts Receivables |
1
|
107
|
212
|
276
|
454
|
|
| Other Receivables |
30
|
18
|
15
|
17
|
61
|
|
| Inventory |
20
|
99
|
144
|
165
|
168
|
|
| Other Current Assets |
38
|
102
|
243
|
53
|
75
|
|
| Total Current Assets |
92
|
940
|
847
|
713
|
956
|
|
| PP&E Net |
491
|
601
|
624
|
660
|
652
|
|
| PP&E Gross |
491
|
601
|
624
|
660
|
652
|
|
| Accumulated Depreciation |
52
|
99
|
153
|
214
|
280
|
|
| Intangible Assets |
325
|
566
|
732
|
951
|
1 243
|
|
| Total Assets |
908
N/A
|
2 107
+132%
|
2 203
+5%
|
2 323
+5%
|
2 851
+23%
|
|
| Liabilities | ||||||
| Accounts Payable |
92
|
94
|
153
|
218
|
214
|
|
| Accrued Liabilities |
7
|
70
|
182
|
173
|
92
|
|
| Short-Term Debt |
0
|
45
|
0
|
86
|
146
|
|
| Current Portion of Long-Term Debt |
8
|
20
|
92
|
86
|
110
|
|
| Other Current Liabilities |
290
|
32
|
45
|
91
|
87
|
|
| Total Current Liabilities |
396
|
260
|
472
|
653
|
649
|
|
| Long-Term Debt |
8
|
245
|
210
|
234
|
430
|
|
| Other Liabilities |
22
|
50
|
103
|
116
|
129
|
|
| Total Liabilities |
426
N/A
|
555
+30%
|
784
+41%
|
1 004
+28%
|
1 207
+20%
|
|
| Equity | ||||||
| Common Stock |
360
|
499
|
509
|
509
|
536
|
|
| Retained Earnings |
122
|
109
|
422
|
521
|
426
|
|
| Additional Paid In Capital |
0
|
1 162
|
1 329
|
1 329
|
1 532
|
|
| Other Equity |
0
|
0
|
2
|
2
|
2
|
|
| Total Equity |
482
N/A
|
1 552
+222%
|
1 418
-9%
|
1 320
-7%
|
1 644
+25%
|
|
| Total Liabilities & Equity |
908
N/A
|
2 107
+132%
|
2 203
+5%
|
2 323
+5%
|
2 851
+23%
|
|
| Shares Outstanding | ||||||
| Common Shares Outstanding |
509
|
509
|
509
|
509
|
509
|
|
Switch to:
Switch to:
See Also
Discover More
